Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV et al. N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1714678. [Epub ahead of print].

Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
Auner HW et al. Haematologica. 2017 Dec 7. pii: haematol.2017.181339. doi: 10.3324/haematol.2017.181339. [Epub ahead of print].

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Richardson PG et al. Expert Opin Pharmacother. 2017 Dec;18(18):1975-1985. doi: 10.1080/14656566.2017.1409207. Epub 2017 Dec 1.

The European Medicines Agency Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K et al. Oncologist. 2017 Nov 30. pii: theoncologist.2017-0301. doi: 10.1634/theoncologist.2017-0301. [Epub ahead of print].

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Krishnan A et al. Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.352. [Epub ahead of print].

Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Van Sanden S et al. Oncologist. 2017 Nov 30. pii: theoncologist.2017-0103. doi: 10.1634/theoncologist.2017-0103. [Epub ahead of print].